SciSight Ecosystem
WoS ESCI Q2Scopus Q2SCImago #9,946CAS 4区Gold OA

Asia Pacific Allergy

Country: South Korea•WoS SCIE Quartile: Q2•Scopus SJR: 0.595•SCImago Rank: #9,946•Identifier (ISSN):2233-8276(Print)/2233-8268(Online)•Articles / Year: 39•Estimated Publication Fee (APC): $2,950 USD
Clarivate JCR Index Advisory: Active (ESCI)
Clarivate IF (2026)Q2
2.8
↑ +0.7

Leading citation impact metric from Clarivate Journal Citation Reports

JCR Release Date: 2026-06-17
H-Index (Hirsch Index)
17

17 papers with at least that number of citations each

WoS: ESCIQ2
Self-Citation Rate6.2%
Safe Level (< 15%)Warning Level (> 20%)
Self-citation below 15% indicates strong scholarly independence.
Volume & Open AccessGold OA
39articles/year
100% Gold OA•87.18% Original Research

State Council for Professorship (HĐGSNN) Scoring

Quyết định số 26/QĐ-HĐGSNN ngày 11/7/2025 (Mục quốc tế)

1.75pts
Latest Max Score
Estimated (Dec 26)
Scoring Basis: WoS Q2 có IF ≥ 2.0(IF: 2.8)

HĐGSNN Score History

By article publication year
YearMax ScoreEvaluation DetailsSource
20261.75đ
WoS Q2 có IF ≥ 2.0(IF: 2.8)
🔵 Computed
20251.75đ
WoS Q2 có IF ≥ 2.0(IF: 2.1)
🔵 Computed
20241.50đ
WoS Q2(IF: 1.6)
🔵 Computed
20231.50đ
WoS Q2(IF: 1.7)
🔵 Computed

Note: Domestic journal scores are officially collected from annual HĐGSNN decisions across councils. International journal scores are dynamically computed according to Decision 26/QĐ-HĐGSNN based on quartile and citation metrics in the publication year.

Aims & Scope

Asia Pacific Allergy (AP Allergy) is the official journal of the Asia Pacific Association of Allergy, Asthma and Clinical Immunology (APAAACI). Although the primary aim of the journal is to promote communication between Asia Pacific scientists who are interested in allergy, asthma, and clinical immunology including immunodeficiency, the journal is intended to be available worldwide. To enable scientists and clinicians from emerging societies appreciate the scope and intent of the journal, early issues will contain more educational review material. For better communication and understanding, it will include rational concepts related to the diagnosis and management of asthma and other immunological conditions. Over time, the journal will increase the number of original research papers to become the foremost citation journal for allergy and clinical immunology information of the Asia Pacific in the future.

Topics Covered (Recognized by AI)
MedicineBiology95.6%Immunology90.1%Internal medicine78.2%Allergy52.4%Pathology52.2%Genetics48.2%Asthma42.5%Psychology40%Dermatology33.2%Chemistry32.3%Surgery30.2%Psychiatry29.2%Antibody26.8%Biochemistry25.8%Immunoglobulin E25.2%Pediatrics24.1%Pharmacology20.7%
Primary Research Areas

SCImago & Scopus Journal Intelligence

Global SCImago ranking, SJR prestige index, Scopus coverage, and societal policy impact

Rank #9,946Scopus Q2SCImago Profile
Scopus Coverage:2015-2017, 2019-2025
Scopus Broad Areas:Medicine
Scopus Citation Rank (SJR)Q2
0.595

Weighted prestige citation metric per document indexed in the Scopus database.

Tứ phân vị: Scopus Q2
Scopus H-Index (2025)
17

Measures cumulative publication volume and citation impact.

Scopus Database Indexed (2025)
Citations / Doc (2 years)
2.59

Average citations received per document published in the 2-year window.

2-Year Citation Window
Estimated Publication Fee (APC)
$2,950 USD

Estimated Article Processing Charge for Open Access publication.

Chi phí ước tính / bài báo

Scopus 3-Year Publication & Citation Window

3-Year Citations231
3-Year Documents115
Citable Documents99

Aggregated from Scopus database across the 3-year SJR evaluation window.

Societal Impact & Inclusivity (SCImago)

Policy Citations (Overton)0

Citations in government and international policy documents

Female Author Rate45.9%

Percentage of female authors published in the journal

Real-world societal policy reach and author gender diversity tracked by SCImago.

Scopus Subject Categories

DermatologyQ2
Immunology and AllergyQ3

Chinese Academy of Sciences (CAS) Classification

Major / minor zone classification and CAS Early Warning List history

Major Category (Broad Field):
4区 (Zone 4)Medicine
Minor Category (Specific Field):
4区ALLERGY
CAS Early Warning List History:
Updated annually: 2020 – 2024
2020
Not warned
2021
Not warned
2022
Not warned
2023
Not warned
2024
Not warned

Publishing & Editorial Information

Detailed publisher, peer-review turnaround, and publication cycle specifications

Publisher Review Speed
Updating
Average time to first editorial decision
Online Publication Speed
Updating
Time from acceptance to online publication
Official Acceptance Rate
Updating
Manuscript acceptance rate confirmed by the publisher
Open Access Model
Gold OA
OA publishing option or traditional subscription
Publisher
Asia Pacific Association of Allergy, Asthma and Clinical Immunology
Publication Language
English
Frequency
Periodic
Indexing & Databases
ESCIPubMed

WoS Categories & Quartiles

Detailed JCR / JCI category rankings and quartile breakdown from Clarivate

Clarivate JCR & JCI
CategoryIndexRankQuartile
ALLERGY
JCRESCI
20/40Q2
ALLERGY
JCIESCI
25/40Q3

Annual Historical Statistics & Publications

Track annual publication volume, total citations, and Impact Factor evolution

12 year
YearImpact FactorArticles / YearTotal Citations
2026—613
20252.18169
20241.634117
20231.741371
2022—46313
2021—49418
2020—45605
2019—36446
2018—42805
2017—38565
2016—40683
2015—37801
Academic Metric Intelligence

Journal Metrics & Citation Visualizations

Impact Factor Trend (2018–2024)

Clarivate IF trend for Asia Pacific Allergy

WoS Q2
12232023202420252.10
Annual Impact Factor Metric
2025:2.1

Total Cites vs Self-Cites

Evaluation of scholarly independence and citation reach

Total citations steady growth
Self-citation: 6.2%

Citations per Document

Citation metric windows across 2, 3, and 4 years

Cites / Doc (4 years)Cites / Doc (3 years)Cites / Doc (2 years)

Similar Journals in Discipline

Journals in the same research field with comparable impact metrics

Record UUID: 4350baa9-d72f-4212-a0e0-87240932956f
Database Updated: 2026-09-30